Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats
Open accessThe DOI matches its Crossref record; 62 of the 68 references it cites were found in a registry or an index; 11 of the 26 sources its claims cite were checked for support.
Abstract
PGP (Semax), has been used successfully in the treatment of patients with severe impairment of cerebral blood circulation. However, its molecular mechanisms of action within the brain are not yet fully understood. Previously, we used the transient middle cerebral artery occlusion (tMCAO) model to study the damaging effects of ischaemia-reperfusion on the brain transcriptome in rats. Here, using RNA-Seq analysis, we investigated the protective properties of the Semax peptide at the transcriptome level under tMCAO conditions. We have identified 394 differentially expressed genes (DEGs) (>1.5-fold change) in the brains of rats at 24 h after tMCAO treated with Semax relative to saline. Following tMCAO, we found that Semax suppressed the expression of genes related to inflammatory processes and activated the expression of genes related to neurotransmission. In contrast, ischaemia-reperfusion alone activated the expression of inflammation-related genes and suppressed the expression of neurotransmission-related genes. Therefore, the neuroprotective action of Semax may be associated with a compensation of mRNA expression patterns that are disrupted during ischaemia-reperfusion conditions.
Overview
CoChat Summary
## TL;DR
This rat tMCAO transcriptomics study found that Semax changed the brain subcortical transcriptome mainly at 24 h after ischemia-reperfusion, not at 4.5 h. The peptide shifted expression in the opposite direction of ischemia-reperfusion alone, suppressing inflammatory genes and activating neurotransmission-related genes.
## Key findings
- RNA-seq identified 394 differentially expressed genes (DEGs) in IS24 vs IR24 at 24 h after tMCAO, with 191 upregulated and 203 downregulated genes; no significant DEGs were found at 4.5 h (IS4.5 vs IR4.5) using the paper’s threshold of >1.5-fold change and adjusted p < 0.05.
- Compared with ischemia-reperfusion alone, Semax produced an opposite transcriptional pattern: in the IS24 vs IR24 comparison, it suppressed inflammatory genes and activated neurotransmission-related genes; the authors say ischemia-reperfusion did the reverse.
- In overlap analysis, the paper reports 313 DEGs shared between IS24 vs IR24 and IR24 vs SH24; only Mx1 was upregulated in both, and no DEGs were downregulated in both.
- Functional/pathway analysis found 25 signaling pathways associated with Semax-induced DEGs in IS24 vs IR24; among the pathways highlighted, Semax upregulated genes linked to Neuronal System, GPCR signaling, Transmission across Chemical Synapses, and downregulated genes linked to Innate Immune System, Neutrophil degranulation, Cytokine Signalling in Immune system.
## Methods
- Design: Experimental rat study using a transient middle cerebral artery occlusion (tMCAO) model with reperfusion, comparing Semax-treated and saline-treated ischemia-reperfusion groups, plus sham-operated controls.
- Sample/data: 2-month-old male Wistar rats; RNA-seq comparisons used groups of n = 3 per RNA-seq comparison group, and RT-PCR validation used at least five animals per comparison group.
- Main analysis: RNA-seq of subcortical brain tissue (including lesion focus), differential expression by Cuffdiff with >1.5-fold change and Benjamini–Hochberg adjusted p < 0.05; validation by real-time RT-PCR; functional annotation via DAVID, GSEA, gProfileR, and PANTHER.
## Limitations
- The paper explicitly states its major limitation was the lack of protein-level confirmation of the detected mRNA changes and lack of functional evidence supporting those mRNA changes.
- The text also makes evident that the RNA-seq comparison groups were small (n = 3), which may limit statistical power; this is evident from the methods, not stated as a limitation.
- The study is restricted to a rat tMCAO model and subcortical brain tissue, so direct clinical generalization is limited; this is evident from the study design, not stated as a limitation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
8 Valid · 0 Not valid · 1 Not checked · 27 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previously, using models of global incomplete cerebral ischaemia we have shown the effect of Semax on the expression of the limited number of genes that encode neurotrophic factors and their receptors [23,24,25].”
§ Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [23] Medvedeva, 2013, Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain, J. Mol. Neurosci. source
- Partly supportedcites [24] Dmitrieva, 2010, Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia, Cell. Mol. Neurobiol. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says the study examined Semax’s effect on a limited set of neurotrophin and receptor genes, and the Discussion reports changes in their expression. But the Focal Cerebral Ischemia methods section (page unavailable) describes permanent middle cerebral artery occlusion in rats—a focal ischemia model, not global incomplete cerebral ischemia. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [25] Stavchansky, 2011, The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: A pilot study, J. Mol. Neurosci. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This model reflects events that occur in ischaemic stroke in humans after treatment with thrombolytic agents [28,29].”
§ Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats > 1. Introduction
What the sources say
- Supportedcites [28] Nieswandt, 2011, Ischaemic stroke: A thrombo-inflammatory disease?, J. Physiol. source
The Abstract (p.1) states that human patients 'can develop progressive stroke despite reperfusion of previously occluded major intracranial arteries, a process referred to as reperfusion injury which can be reproduced in the mouse model of transient middle cerebral artery occlusion (tMCAO)'. The Introduction ties that reperfusion to thrombolytic therapy: tPA is the only approved treatment and 'a considerable number of patients show secondary infarct growth despite successful vessel recanalization'. The Introduction passage on tMCAO (filament removal after 1 h allowing reperfusion, complete MCA infarct within 24 h) confirms the model reproduces those post-thrombolysis events, so the paraphrase is supported. (LLM, conf=0.86)
- Partly supportedcites [29] Ryang, Y.-M., Dang, J., Kipp, M., Petersen, K.-U., Fahlenkamp, A.V., Gempt, J., Wesp, D., Rossaint, R., Beyer, C., and Coburn, M. (2011). Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neurosci., 12. sourceExperimental — accuracy not yet measured
The Methods (page unavailable) describe a rat tMCAO model in which blood flow was restored by removing the occluding thread. The Background (page unavailable) discusses thrombolytic treatment in human stroke, but the paper does not state that thread-removal reperfusion reflects events after thrombolysis in humans. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Using microchips RatRef-12 BeadChips, it was shown that peptide Semax affects the expression of genes related to the immune and vascular systems in rat fronto-parietal cortex after permanent middle cerebral artery occlusion (pMCAO) [26,27].”
§ Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats > 1. Introduction
What the sources say
- Supportedcites [26] Medvedeva, E.V., Dmitrieva, V.G., Povarova, O.V., Limborska, S.A., Skvortsova, V.I., Myasoedov, N.F., and Dergunova, L.V. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: Genome-wide transcriptional analysis. BMC Genomics, 15. source
The Results report Semax-induced expression changes in immune- and vascular-system genes after pMCAO. The Methods (Experimental groups) identify the sampled tissue as rat frontoparietal cortex, and the Results (Semax-induced increase and decrease in gene expression) identify the RatRef-12 Expression BeadChip used for the analysis. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [27] Medvedeva, 2017, Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats, Mol. Genet. Genomics source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previously, using RNA-Seq, we identified 1939 DEGs (1109 up- and 839 downregulated) under IR conditions after tMCAO at 24 h versus sham operation at 24 h after surgical procedure (IR24 versus SH24) [32].”
§ Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats > 3. Results > 3.5. Differences in Rat Brain Transcriptomes Following Ischaemia and after Semax Administration Previously, using RNA-Seq, we identified 1939 DEGs (1109 up- and 839 downregulated) under IR conditions after tMCAO at 24 h versus sham operation at 24 h after surgical procedure (IR24 versus SH24) [32]. In this study, we identified 313 DEGs that overlapped for IS24 versus IR24 and IR24 versus SH24 (Figure 3a, Supplementary Table S5). Venn diagrams with only up-regulated DEGs and only down-regulated DEGs in both conditions are shown in Figure 3b,c. We found only the Mx1 gene, which encodes an interferon-induced GTP-binding protein was upregulated in both IS24 versus IR24 and IR24 versus SH24, simultaneously (Figure 3b), and did not found DEGs which were downregulated in both conditions (Figure 3c). It should be noted that Semax initiated mRNA expression that counteracted the effects of IR injury. Hierarchical cluster analysis shows the Semax increases the expression levels of genes that reduce expression by the action of ischaemia and vice versa, that is, it compensates for the effect of ischaemia (Figure 3d). In particular, we found 155 up- and 157 downregulated DEGs in IS24 versus IR24 that counteracted IR in IR24 versus SH24 (Supplementary Table S5). The top 10 genes with the greatest fold change in IS24 versus IR24 are presented in Figure 3e. The figure shows that the expression levels of genes Gpr6, Neu2, Hes5, Gpr88, and Drd2 was increased by up to 2.5-fold in IS24 versus IR24 and was decreased by up to 4-fold in IR24 versus SH24. Simultaneously, the expression of genes Glycam1, S100a9, Ccl6, Gh1, and Hspa1(a,b) was decreased by 3-fold in IS24 versus IR24 and was increased by up to 5-fold in IR24 versus SH24. Moreover, 81 genes (35 up- and 46 downregulated) altered their expression in IS24 versus IR24 but did not alter it in IR24 versus SH24 (Figure 3a, Supplementary Table S6). These DEGs predominantly have catalytic and binding activity, but additionally have receptor and signal transducer (Gabrb1, Grin2b, Folr1, Bdnf), as well as transporter (Kcnj13, Slc1a2, Slco1a5) activity (Supplementary Table S7).
What the sources say
- Partly supportedcites [32] Dergunova, L.V., Filippenkov, I.B., Stavchansky, V.V., Denisova, A.E., Yuzhakov, V.V., Mozerov, S.A., Gubsky, L.V., and Limborska, S.A. (2018). Genome-wide transcriptome analysis using RNA-Seq reveals a large number of differentially expressed genes in a transient MCAO rat model. BMC Genomics, 19. sourceExperimental — accuracy not yet measured
The Results section (‘RNA-Seq analysis of gene expression profiles in tMCAO model conditions’; page unavailable) reports 1,939 DEGs for IR24 versus SH24 using RNA-Seq, matching the comparison and total. Our copy does not state the claimed breakdown of 1,109 upregulated and 839 downregulated genes; those figures also sum to 1,948, not 1,939. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, in models of brain ischaemia and inflammation, α-MSH exhibits strong anti-inflammatory, neurogenic and neuroprotective effects [65,66,67].”
§ Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats > 4. Discussion Drugs, based on native regulatory peptides, are used to treat various pathological conditions, including peptide drugs that help restore brain function after acute cerebrovascular accidents. In studies to investigate the molecular mechanisms of action of such neuroprotective peptides, experimental models of ischaemia in animals are of great importance. For example, the neuroprotective effects of orexin (OxA) [50] and poly-arginine R18 and NA-1 peptides [51], as well as the anti-inflammatory and anti-oxidant effects of cordymin peptide [52] were identified in studies employing middle cerebral artery occlusion-induced focal cerebral ischaemia in rats. Semax, a nootropic neuropeptide, has been used in neurological practice for many years in the treatment of acute and chronic disorders, including ischaemic stroke and its consequences [14,15,53]. However, its molecular mechanisms of action are not yet fully understood. There are many examples of the use of transcriptome analysis to study the mechanisms of action of a number of peptides including PACAP38 [54], Sal-like 4 peptide [55] and OxA [50]. The first genome-wide analysis of Semax action on the rat brain transcriptome was conducted using a permanent MCAO model that was induced by direct permanent electrical coagulation of the distal segment of the left middle cerebral artery [26,27]. The genome-wide biochip data analysis detected DEGs associated with several biological processes and signalling pathways. In the first hours after pMCAO, a significant increase in the expression of transcription factor genes was observed in the presence of Semax. These genes encode proteins that trigger signalling to correct the destructive processes associated with ischaemic conditions. Semax also stimulated the expression of genes that encode growth factors involved in trophic and protective processes, as well as the vascularization of damaged tissues. Additionally, Semax administration had a significant effect on the expression of genes associated with the immune response [26,27]. In the current study of the protective mechanisms of action of the Semax peptide, we aimed to identify the DEGs, as well as the biological processes and signalling pathways involved in the response of rat brain cells to Semax action under ischaemia–reperfusion (IR) conditions. Therefore, we used the tMCAO model, which involves occlusion of the MCA and subsequent restoration of blood flow [22,56]. Importantly, the tMCAO model in rats replicates circumstances that arise in the human brain after ischaemic stroke treated with thrombolytic medications [28,29]. MRI (Supplementary Table S2 and Figure S1) and histopathological analysis (Figure 1) detected the ischaemic focus and the penumbra region in the subcortical structures of the brain after tMCAO. A study of the molecular mechanisms of cell death under pMCAO and tMCAO conditions, conducted by Ford et al. [57] revealed molecular functions and biological processes unique to each model. Genes uniquely altered by tMCAO included a number of genes related to inflammatory and oxidative stress, whereas pMCAO led to the induction of genes that were more associated with metabolic activity and cellular signalling [57]. In addition, reperfusion after ischaemia leads to additional injury, including disturbance of the blood-brain barrier via destruction of the endothelial microvascular brain cells, and damage of brain cells through the accumulation of excess oxygen radicals and apoptosis [22,58,59,60,61]. Using RNA-Seq to determine the mRNA expression profile in the subcortical structures of rat brain in response to Semax administration, a significant effect of Semax was identified at 24 h after tMCAO. We identified 394 DEGs (>1.5-fold change) following Semax administration at 24 h after tMCAO, but there were no DEGs identified following Semax administration at 4.5 h after tMCAO. An analysis of the expression of 10 genes by real-time RT-PCR confirmed the RNA-Seq results. A large number of genes, altered by Semax in the tMCAO model, encode transcripts and proteins involved in cellular processes, metabolic processes, biological regulation, responses to external stimuli and multicellular organism-associated processes.
What the sources say
- Supportedcites [65] Giuliani, 2017, Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives, Prog. Neurobiol. source
Section 4.1 (p. 14) states that α-MSH 'reduced brain inflammation in transient global and focal cerebral ischemia in mice' and that α-MSH's neuroprotective effect was 'confirmed... in other models of global and focal cerebral ischemia in rats'; p. 15 adds that melanocortins act 'through antagonism of excitotoxic, inflammatory and apoptotic responses' with reduced TNF-α/IL-6 and Table 2 (p. 78) lists ↓ cortical TNF-α, IL-1β and TH1 response for α-MSH. The neurogenic component is in the same ischemia chapter: §4.2 (pp. 15-17) describes melanocortin-stimulated neurogenesis and Zif268-mediated integration of newborn neurons after ischemic stroke, concluding 'Induction of neuroprotection and neurogenesis...' (p. 17), echoed in the Abstract (p. 5) 'they promote neurogenesis'. One caveat of specificity only: much of the neurogenesis evidence in the review is with the analogue NDP-α-MSH rather than native α-MSH, and §4.2 hedges that melanocortins 'might' promote recovery via neurogenesis, but the overall triad of anti-inflammatory, neurogenic and neuroprotective effects in ischaemia/inflammation models is what our copy reports. (LLM, conf=0.80)
- Partly supportedcites [66] Lisak, R.P., and Benjamins, J.A. (2017). Melanocortins, Melanocortin Receptors and Multiple Sclerosis. Brain Sci., 7. sourceExperimental — accuracy not yet measured
Sections 5.2 and 7 report anti-inflammatory effects of α-MSH and neuroprotection by melanocortins in CNS injury and neuroinflammatory models. Section 6.2 mentions neurogenesis in an Alzheimer’s model following MC4R activation, but the copy does not establish the claimed combination of effects for α-MSH in models of brain ischaemia and inflammation. Page numbers were not available in the indexed passages. (LLM, conf=0.86)
- Partly supportedcites [67] Mykicki, 2016, Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease, Sci. Transl. Med. sourceExperimental — accuracy not yet measured
Our copy supports the anti-inflammatory and neuroprotective parts in models of CNS (neuro)inflammation: the Results section 'MSH, by binding to Mc1r, ameliorates ongoing EAE' reports that α-MSH 'completely protected mice from developing clinical signs, which was associated with reduced numbers of inflammatory foci and decreased CNS demyelination', and the DISCUSSION states 'we detected a strong and direct neuroprotective effect of NDP-MSH in mouse as well as human neurons'. However, the paper's models are MOG-induced EAE, Devic's disease and glutamate excitotoxicity — searched terms 'cerebral ischemia/stroke/middle cerebral artery occlusion/oxygen-glucose deprivation' return no ischaemia experiment, so 'models of brain ischaemia' is not supported here. Likewise no neurogenic/neurogenesis effect is reported (searched 'neurogenesis, progenitor differentiation, BrdU, Ki67, doublecortin'); human neuronal cells differentiated from progenitors are only used as a culture system. Note also that the 'strong' neuroprotection in this paper is attributed to the synthetic analogue NDP-MSH, with the DISCUSSION suggesting naturally occurring α-MSH 'might not be potent enough to induce neuroprotection and BBB repair'. (LLM, conf=0.75)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
19 more claims
Create a free account to see all 36 claims and to verify the 2 references still open.
- It may state two separate claims as one. 9
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been shown that Semax decreases ischemic brain damage in clinical and animal studies by inducing the expression of neurotrophins and their receptors [45,46,47,48,49,50].”
From Protective Effects of PGC-1α Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis (2021) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A genome-wide RNA-Seq analysis revealed that, in the rat transient middle cerebral artery occlusion (tMCAO) model, Semax suppressed the expression of inflammatory genes and activated the expression of neurotransmitter genes.”
From Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion (2021) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“We have previously shown that, in the subcortical structures of the brain containing the focus of ischemic damage, Semax initiates a large-scale neurotransmitter and anti-inflammatory response that counteracts ischemia–reperfusion [17].”
From Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion (2021) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The results of Filippenkov et al. are consistent with our data on the anti-inflammatory effects of Semax. Using RNA-Seq analysis, the authors showed that Semax suppressed the inflammatory pathways and activated the brain’s neurotransmitter signaling pathways after focal ischemia [48].”
From Protective Effects of PGC-1α Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis (2021) · cites this paper as [48]
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 4×
“Additionally, similar results were obtained using GSEA (KEGG, Reactome, BioCarta, PID) and gProfileR (KEGG, Reactome, WikiPathways).”
MethodInfluentialSingle-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426 · cited 1×
“Total RNA from the subcortex, was isolated using TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and acid guanidinium thiocyanate-phenol-chloroform extraction [39].”
MethodSystematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 1×
“8, Laboratory of Human Retrovirology and Immunoinformatics, Frederick, MD, USA) [43], Gene Set Enrichment Analysis (GSEA) [44], gProfileR [45] and The PANTHER database (Protein ANalysis THrough Evolutionary Relationships) [46] were used to annotate the functions of the differentially expressed genes.”
MethodThe MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303 · cited 1×
“Two reference genes Gapdh and Rpl3 were used to normalize the cDNA samples [40].”
MethodPfaffl, M. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.e36 · Cited by 7,376 · cited 1×
“Calculations were performed using BestKeeper, version 1 (gene-quantification, Freising-Weihenstephan, Bavaria, Germany) [41] and Relative Expression Software Tool (REST) 2005 software (gene-quantification, Freising-Weihenstephan, Bavaria, Germany) [42].”
MethodPfaffl, M. W., Tichopad, A., Prgomet, C., & Neuvians, T. P. (2004) · Biotechnology Letters · doi:10.1023/b:bile.0000019559.84305.47 · Cited by 5,065 · cited 2×
“Calculations were performed using BestKeeper, version 1 (gene-quantification, Freising-Weihenstephan, Bavaria, Germany) [41] and Relative Expression Software Tool (REST) 2005 software (gene-quantification, Freising-Weihenstephan, Bavaria, Germany) [42].”
MethodIschemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Heatmapper: web-enabled heat mapping for all
Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J. R., Maciejewski, A., & Wishart, D. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw419 · Cited by 2,285
Mi, H., Huang, X., Muruganujan, A., Tang, H., Mills, C., Kang, D., & Thomas, P. D. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1138 · Cited by 1,874 · cited 1×
“8, Laboratory of Human Retrovirology and Immunoinformatics, Frederick, MD, USA) [43], Gene Set Enrichment Analysis (GSEA) [44], gProfileR [45] and The PANTHER database (Protein ANalysis THrough Evolutionary Relationships) [46] were used to annotate the functions of the differentially expressed genes.”
Methodg:Profiler—a web server for functional interpretation of gene lists (2016 update)
Reimand, J., Arak, T., Adler, P., Kolberg, L., Reisberg, S., Peterson, H., & Vilo, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw199 · Cited by 1,229 · cited 1×
“8, Laboratory of Human Retrovirology and Immunoinformatics, Frederick, MD, USA) [43], Gene Set Enrichment Analysis (GSEA) [44], gProfileR [45] and The PANTHER database (Protein ANalysis THrough Evolutionary Relationships) [46] were used to annotate the functions of the differentially expressed genes.”
Research works printed but not linked: 4
- Ashmarin, 1995, Design and Investigation of an ACTH(4-10) Analog Lacking D-Amino Acids and Hydrophobic Radicals, Neurosci. Res. Commun., 16, 105
- 1997, The Rat Brain in Stereotaxic Coordinates, 3rd edn. By George Paxinos and Charles Watson. (Pp. xxxiii+80; illustrated; f$69.95 paperback; ISBN 0 12 547623; comes with CD-ROM.) San Diego: Academic Press. 1996, J. Anat., 191, 315
- (2020, May 10). National Center for Biotechnology Information, Available online: https://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP148632.
- (2020, May 10). National Center for Biotechnology Information, Available online: https://www.ncbi.nlm.nih.gov/sra/PRJNA491404.
Cited by
Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries
Dergunova, L. V., Filippenkov, I. B., Limborska, S. A., & Myasoedov, N. F. (2023) · Genes · doi:10.3390/genes14050953 · Cited by 40
“Previously, we have described, in detail, medical technologies for the treatment of IS using drugs based on natural regulatory peptides [27,28,32].”
BackgroundSelf-citationDifferential gene expression in the contralateral hemisphere of the rat brain after focal ischemia
Filippenkov, I. B., Remizova, J. A., Denisova, A. E., Stavchansky, V. V., Golovina, K. D., Gubsky, L. V., Limborska, S. A., & Dergunova, L. V. (2023) · Scientific Reports · doi:10.1038/s41598-023-27663-8 · Cited by 20
Self-citationFilippenkov, I. B., Stavchansky, V. V., Глазова, Н. Ю., Sebentsova, E. A., Remizova, J. A., Valieva, L. V., Levitskaya, N. G., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810054 · Cited by 23
“Following the transient middle cerebral artery occlusion (tMCAO) model, Semax suppressed the expression of genes related to inflammatory processes and activated the expression of genes related to neurotransmission [70].”
BackgroundSelf-citationFilippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Valieva, L. V., Remizova, J. A., Mozgovoy, I. V., Zaytceva, E. I., Gubsky, L. V., Limborska, S. A., & Dergunova, L. V. (2021) · Genes · doi:10.3390/genes12121870 · Cited by 18
Self-citationSudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126179 · Cited by 15
“We have previously shown that, in the subcortical structures of the brain containing the focus of ischemic damage, Semax initiates a large-scale neurotransmitter and anti-inflammatory response that counteracts ischemia–reperfusion [17].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Y., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V.
- Affiliations
- Russian Academy of Sciences (RU)
- Pirogov Russian National Research Medical University (RU)
- Ministry of Health of the Russian Federation (RU)
- Corresponding author
- Filippenkov, Ivan B.
- ORCID
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2020-06-22
- Volume
- 11
- Issue
- 6
- Pages
- 681
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC7350263
- OpenAlex
- W3036055014
- Cited by
- 29
- References
- 68
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 1
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Russian Science Foundation (19-14-00268)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Semax, neuroprotection, transient middle cerebral artery occlusion, brain transcriptome, differentially expressed genes, neuroinflammation, neurotransmission, mRNA expression patterns
- MeSH terms
- RNA-Seq, Adrenocorticotropic Hormone, Animals, Brain, Brain Ischemia, Disease Models, Animal, Humans, Peptide Fragments, Reperfusion Injury, Infarction, Middle Cerebral Artery, Rats, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. https://app.cochat.ai/papers/10.3390/genes11060681
- The paper
- Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Y., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes. https://doi.org/10.3390/genes11060681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.